Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 104 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Recurrent Glioblastoma Surgical Resection Clear all
Withdrawn Phase 2 Interventional

A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma

NCT04629209
View directory record Official record
Conditions
Glioblastoma
Interventions
ONC201
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 23, 2023 · Synced Sep 24, 2026, 4:05 PM EDT
Terminated Phase 2 Interventional Results available

Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas

NCT01966809
View directory record Official record
Conditions
Brain Tumor, Recurrent
Interventions
Photofrin photodynamic therapy.
Drug
Lead sponsor
Harry T Whelan, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Sep 24, 2026, 4:05 PM EDT
Recruiting No phase listed Observational

The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma

NCT06273176
View directory record Official record
Conditions
Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme of Brain, Astrocytoma, Malignant, Brain Neoplasms, Brain Neoplasms, Adult, Malignant, Brain Neoplasms, Adult, Recurrent Adult Brain Tumor, Recurrent Glioblastoma
Interventions
Awake mapping under local anesthesia, Asleep mapping under general anesthesia, Resection under general anesthesia without mapping
Procedure
Lead sponsor
Erasmus Medical Center
Other
Eligibility
Up to 90 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
San Francisco, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Sep 24, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma

NCT00979173
View directory record Official record
Conditions
Glioma
Interventions
AC480
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2014 · Synced Sep 24, 2026, 4:05 PM EDT
Recruiting Phase 1 Interventional

D2C7-IT + 2141-V11 Combination Post-resection in rGBM

NCT06455605
View directory record Official record
Conditions
Recurrent Glioblastoma IDH Wildtype
Interventions
D2C7-IT, 2141 V11
Drug
Lead sponsor
Darell Bigner
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 24, 2026, 4:05 PM EDT
Withdrawn Phase 1 Interventional

Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma

NCT05341947
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Activated T cells
Biological
Lead sponsor
Jeremy Rudnick, M.D
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Sep 24, 2026, 4:05 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Participants With Recurrent Gliomas

NCT01986348
View directory record Official record
Conditions
Glioblastoma, Glioma
Interventions
Selinexor
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 24, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection

NCT01240460
View directory record Official record
Conditions
Glioblastoma, Astrocytoma, Grade IV
Interventions
XL765 (SAR245409), XL147 (SAR245408)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Sep 24, 2026, 4:05 PM EDT
Completed Phase 2 Interventional Results available

GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

NCT00980343
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
Interventions
vismodegib, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Sep 24, 2026, 4:05 PM EDT
Recruiting Early Phase 1 Interventional

A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions

NCT06072586
View directory record Official record
Conditions
High Grade Glioma, Glioblastoma
Interventions
BDTX-1535, BDTX-1535 combined with radiation therapy, BDTX-1535 combined with temozolomide and radiation therapy
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Chandler, Arizona • Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Sep 24, 2026, 4:05 PM EDT
Active, not recruiting Phase 1 Interventional Results available

Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

NCT04477200
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma, Newly Diagnosed Gliosarcoma, Newly Diagnosed Astrocytoma, Grade IV
Interventions
Mycophenolate Mofetil, Radiation Therapy, Re-resection (as part of standard of care), Temozolomide
Drug · Radiation · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 24, 2026, 4:05 PM EDT
Recruiting Phase 3 Interventional

Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM

NCT05902169
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, GBM
Interventions
SonoCloud-9 (SC9), Carboplatin, Lomustine, Temozolomide
Device · Drug
Lead sponsor
CarThera
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 24, 2026, 4:05 PM EDT
Active, not recruiting Early Phase 1 Interventional

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

NCT05076513
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme, Glioma, GBM, Glioma, Malignant, Glioblastoma Multiforme of Brain
Interventions
Niraparib, Radiation therapy
Drug · Radiation
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 24, 2026, 4:05 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma

NCT02315534
View directory record Official record
Conditions
Glioblastoma
Interventions
BBI608, Temozolomide
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Sep 24, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors

NCT00003484
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma
Interventions
carmustine, irinotecan hydrochloride, surgical procedure, iodine I 131 monoclonal antibody 81C6
Drug · Procedure · Radiation
Lead sponsor
Darell D. Bigner, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2015 · Synced Sep 24, 2026, 4:05 PM EDT
Completed Early Phase 1 Interventional

LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients

NCT04391595
View directory record Official record
Conditions
Glioblastoma, GBM, Glioma
Interventions
Abemaciclib, LY3214996
Drug
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Sep 24, 2026, 4:05 PM EDT
Completed Phase 1 Interventional

Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma

NCT04019002
View directory record Official record
Conditions
Glioblastoma Multiforme (GBM)
Interventions
Hyperpolarized 13C Pyruvate
Drug
Lead sponsor
Susan Chang
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 24, 2026, 4:05 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers

NCT03539731
View directory record Official record
Conditions
Healthy Subject, Intracranial Neoplasm, Glioblastoma
Interventions
Fluorine F 18 DASA-23, Positron Emission Tomography
Drug · Procedure
Lead sponsor
Guido A. Davidzon, MD, SM
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 11, 2024 · Synced Sep 24, 2026, 4:05 PM EDT
Terminated Phase 2 Interventional

Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab

NCT04681677
View directory record Official record
Conditions
Glioblastoma, Recurrent Glioblastoma, GBM, Recurrent GBM
Interventions
Radiation: Intra-operative Radiation Therapy - IORT, Bevacizumab
Radiation · Drug
Lead sponsor
Xoft, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Sep 24, 2026, 4:05 PM EDT
Recruiting Phase 2 Interventional

Lerapolturev (PVSRIPO) in GBM

NCT06177964
View directory record Official record
Conditions
Recurrent Supratentorial Glioblastoma
Interventions
Lerapolturev, Lomustine Pill
Drug
Lead sponsor
Darell Bigner
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 24, 2026, 4:05 PM EDT
Recruiting Early Phase 1 Interventional

Clinical Trial of BMS-986504 in Recurrent GBM Patients

NCT06883747
View directory record Official record
Conditions
Glioblastoma WHO Grade IV
Interventions
BMS-986504
Drug
Lead sponsor
Nader Sanai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 24, 2026, 4:05 PM EDT
Recruiting Not applicable Interventional

Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

NCT05979064
View directory record Official record
Conditions
Glioma, Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme of Brain, GBM, Brain Cancer, High Grade Glioma
Interventions
Laparoscopically harvested omental tissue autograft
Procedure
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Sep 24, 2026, 4:05 PM EDT
Active, not recruiting Early Phase 1 Interventional

AB154 Combined With AB122 for Recurrent Glioblastoma

NCT04656535
View directory record Official record
Conditions
Glioblastoma
Interventions
Zimberelimab, Domvanalimab, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
San Francisco, California • New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 24, 2026, 4:05 PM EDT
Recruiting Early Phase 1 Interventional

Implantable Microdevice In Primary Brain Tumors

NCT04135807
View directory record Official record
Conditions
Grade II Glioma, Grade III Glioma, Grade IV Glioma, Astrocytoma, Oligodendroglioma of Brain, Anaplastic Astrocytoma of Brain, Anaplastic Oligodendroglioma, Glioblastoma
Interventions
Microdevice
Combination Product
Lead sponsor
Oliver Jonas
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Sep 24, 2026, 4:05 PM EDT